Format

Send to

Choose Destination
J Clin Invest. 2011 Apr;121(4):1244-7. doi: 10.1172/JCI46430. Epub 2011 Mar 23.

The adaptive stroma joining the antiangiogenic resistance front.

Author information

1
Tumor Angiogenesis Group, Translational Research Laboratory, Catalan Institute of Oncology - IDIBELL, L'Hospitalet de Llobregat, Spain. ocasanovas@iconcologia.net

Abstract

Resistance to antiangiogenic therapies in cancer involves both tumor cells and stromal components, but their relative contributions differ in each cancer subtype. In this issue of the JCI, Cascone et al. describe a stromal adaptation to antiangiogenic therapy in non-small cell lung carcinoma (NSCLC) models that include EGFR-driven vascular remodeling promoting resistance to VEGF inhibition. Their results suggest that the added benefit of dual VEGF/R and EGFR targeting in these models could be clinically relevant to fight resistance in NSCLC patients.

PMID:
21436579
PMCID:
PMC3069791
DOI:
10.1172/JCI46430
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center